Q2 2026 saw 31% revenue and 27% adjusted EBITDA growth, driven by new Performance Suite launches and strong client renewals. Full-year guidance was raised, with 2027 revenue growth expected above 25% despite Medicaid headwinds. AI initiatives and new contracts support long-term margin and growth targets.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.